Friday - September 12, 2025
IMFINZI (durvalumab) Granted Priority Review and Breakthrough Therapy Designation in the US for Patients With Resectable Early-Stage Gastric and Gastroesophageal Junction Cancers
July 29, 2025
WILMINGTON, Delaware, July 29 -- AstraZeneca, a biopharmaceutical company, issued the following news release:

* * *

IMFINZI (durvalumab) granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers

Based on MATTERHORN Phase III trial results which demonstrated a statistically significant and clinically meaningful event-free survival benefit

If appro . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products